“…NMDA activation causes striatal neurons to dephosphorylate and thereby to inactivate the protein phosphatase inhibitor DARRP-32 (Halpain et al, 1990), an important regulator of dopaminergic neurotransmission , whose activity may be necessary for the potentiation of NMDA receptors by protein kinase A (Blank et al, 1997). NMDA receptors participate in the regulation of striatal synaptic plasticity, through processes such as long-term potentiation of synaptic strength (Calabresi et al, 1992;Walsh and Dunia, 1993;Garcia-Munoz et al, 1996). Striatal lesioning with the NMDA agonist quinolinic acid mimics Huntington's disease (Beal et al, 1986(Beal et al, , 1991DiFiglia, 1990;Roberts et al, 1993;Figueredo-Cardenas et al, 1994), a hereditary neurodegenerative disorder that primarily affects striatal projection neurons and spares interneurons (Ferrante et al, 1987a,b;Reiner et al, 1988;Harrington and Kowall, 1991;Albin et al, 1992;Augood et al, 1996).…”